Significant Ownership of SUVRETTA CAPITAL MANAGEMENT, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for SUVRETTA CAPITAL MANAGEMENT, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Andrew Nathanson - Andrew Nathanson, General Counsel and Chief Compliance Officer
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow SUVRETTA CAPITAL MANAGEMENT, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from SUVRETTA CAPITAL MANAGEMENT, LLC
Significant Ownership of SUVRETTA CAPITAL MANAGEMENT, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | Common Stock, par value $0.0001 | 44% | $249,200,088 | +$30,000,153 | 17,761,945 | +14% | SUVRETTA CAPITAL MANAGEMENT, LLC | 07 Nov 2025 |
| IFRX | InflaRx N.V. | Common Shares, nominal value (euro)0.12 per share | 16% | $49,537,246 | +$32,400,000 | 22,933,910 | +189% | Montanova Capital, LLC | 30 Jun 2026 |
| MOLN | MOLECULAR PARTNERS AG | Common Shares, CHF 0.10 nominal value per share | 11% | $17,696,249 | 4,284,806 | SUVRETTA CAPITAL MANAGEMENT, LLC | 15 Jun 2021 | ||
| WHWK | Aadi Bioscience, Inc. | Common Stock, par value $0.0001 per share | 10% | $7,280,365 | 4,727,510 | SUVRETTA CAPITAL MANAGEMENT, LLC | 04 Mar 2025 | ||
| MANE | Veradermics, Inc | Common Stock, par value $0.00001 | 9.9% | $287,041,925 | +$215,344 | 4,172,121 | +0.08% | SUVRETTA CAPITAL MANAGEMENT, LLC | 01 May 2026 |
| DBVT | DBV Technologies S.A. | Ordinary shares, nominal value 0.10 euro per share | 9.9% | $129,451,408 | 15,176,015 | SUVRETTA CAPITAL MANAGEMENT, LLC | 07 Apr 2025 | ||
| AVBP | ArriVent BioPharma, Inc. | Common Stock, $0.0001 Par Value per Share | 9.9% | $75,183,720 | 3,412,788 | Suvretta Capital Management, LLC | 30 Jun 2025 | ||
| ZURA | Zura Bio Limited | Class A Ordinary Shares, par value $0.0001 per share | 9.9% | $57,431,306 | +$23,862,290 | 9,524,263 | +71% | Suvretta Capital Management, LLC | 31 Mar 2026 |
| KURA | Kura Oncology, Inc. | Common Stock, par value $0.0001 per share | 9.7% | $103,591,098 | +$12,254,218 | 8,575,422 | +13% | Montanova Capital, LLC | 30 Jun 2026 |
| IMTX | Immatics N.V. | ordinary shares, nominal value (euro)0.01 per share | 8.3% | $117,496,354 | -$8,820,000 | 11,190,129 | -7% | SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
| CMPX | Compass Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 8.2% | $44,559,662 | +$21,967,265 | 14,101,159 | +97% | Suvretta Capital Management, LLC | 13 Aug 2025 |
| REPL | Replimune Group, Inc. | Common Stock, par value $0.001 per share | 7.9% | $73,492,080 | +$26,545,264 | 6,609,000 | +57% | Montanova Capital, LLC | 30 Jul 2026 |
| BHVN | Biohaven Ltd. | Common Shares, no par value | 7.8% | $116,139,519 | 10,286,937 | SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Dec 2025 | ||
| SNSE | Faeth Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 7.8% | $35,533,612 | 2,020,103 | Suvretta Capital Management, LLC | 15 Jun 2026 | ||
| LXEO | Lexeo Therapeutics, Inc. | Common stock, par value $0.0001 | 7.7% | $32,573,226 | 5,674,778 | SUVRETTA CAPITAL MANAGEMENT, LLC | 06 Apr 2026 | ||
| AURA | Aura Biosciences, Inc. | Common Stock, par value $0.00001 per share | 7.6% | $30,091,360 | +$10,524,518 | 4,701,775 | +54% | Suvretta Capital Management, LLC | 30 Jun 2025 |
| PVLA | Palvella Therapeutics, Inc. | Common stock, $0.001 par value per share | 7.4% | $51,556,256 | +$6,766,571 | 822,400 | +15% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| CAPR | Capricor Therapeutics, Inc. | Common Stock, par value $0.001 per share | 6.6% | $80,730,585 | 3,417,891 | SUVRETTA CAPITAL MANAGEMENT, LLC | 19 Feb 2026 | ||
| ETNB | 89bio, Inc. | Common Stock, par value $0.001 per share | 5.6% | $121,716,000 | -$93,071,712 | 8,280,000 | -43% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| FULC | Fulcrum Therapeutics, Inc. | Common Stock, par value $0.001 per share | 5.5% | $13,472,171 | -$5,074,491 | 3,680,921 | -27% | Montanova Capital, LLC | 30 Jun 2026 |
| MRNS | Marinus Pharmaceuticals, Inc. | Common Stock, par value $0.001 per share | 5.5% | $1,662,437 | +$504,541 | 3,022,612 | +44% | SUVRETTA CAPITAL MANAGEMENT, LLC | 07 Feb 2025 |
| GLUE | Monte Rosa Therapeutics, Inc. | Common stock, par value $0.0001 per share | 4.2% | $85,401,908 | +$4,560,308 | 3,549,539 | +5.6% | Montanova Capital, LLC | 30 Jun 2026 |
| ERAS | Erasca, Inc. | Common Stock, $0.0001 par value per share | 1.1% | $59,631,027 | -$192,123,762 | 3,434,967 | -76% | Suvretta Capital Management, LLC | 31 Mar 2026 |
| ABEO | Abeona Therapeutics Inc. | Common Stock, $0.01 par value | 0.9% | $3,560,000 | -$15,493,120 | 500,000 | -81% | Montanova Capital, LLC | 30 Jun 2026 |
| PEPG | PepGen Inc. | Common Stock, par value $0.0001 per share | 0.9% | $354,000 | -$1,605,900 | 300,000 | -82% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Jun 2025 |
| STRO | Sutro Biopharma, Inc. | Common Stock, $0.001 par value | 0% | $0 | -$75,099,106 | 0 | -100% | SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
Schedules 13D/G Reported by SUVRETTA CAPITAL MANAGEMENT, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.